Informações de Regenxbio Inc

Mais detalhes de Regenxbio Inc Empresa

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.



Código da empresaRGNX

Nome da EmpresaRegenxbio Inc

Data de listagemSep 17, 2015

CEOMr. Curran M. Simpson

Número de funcionários353

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 17

Endereço9804 Medical Center Drive

CidadeROCKVILLE

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal20850

Telefone12405528181

Sitehttps://regenxbio.com/

Código da empresaRGNX

Data de listagemSep 17, 2015

CEOMr. Curran M. Simpson

Executivos da empresa Regenxbio Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

16.11K

-48.81%

Mr. Allan M. Fox, J.D.

Director

--

Dr. David C. (Dave) Stump, M.D.

Independent Director

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 8 de nov

Investidores

Tipos de investidores

Investidores

Proporção

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Outro

64.66%

Investidores

Proporção

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Outro

64.66%

Tipos de investidores

Investidores

Proporção

Investment Advisor/Hedge Fund

33.94%

Investment Advisor

31.21%

Hedge Fund

12.74%

Individual Investor

7.62%

Research Firm

6.92%

Pension Fund

0.28%

Bank and Trust

0.26%

Family Office

0.26%

Private Equity

0.06%

Outro

6.73%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

403

44.05M

87.32%

-5.71M

2025Q2

421

48.19M

95.62%

-3.63M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Redmile Group, LLC

4.78M

9.45%

-19.06K

-0.40%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.27M

8.45%

+348.80K

+8.90%

Jun 30, 2025

The Vanguard Group, Inc.

3.42M

6.77%

-51.80K

-1.49%

Jun 30, 2025

Fox (Allan Mark)

2.90M

5.74%

+7.77K

+0.27%

May 30, 2025

JP Morgan Asset Management

2.99M

5.91%

+38.82K

+1.32%

Jun 30, 2025

State Street Investment Management (US)

1.84M

3.65%

+777.55K

+72.93%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.73M

3.43%

+637.97K

+58.36%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.61M

3.18%

+962.62K

+149.64%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.13M

2.23%

+21.57K

+1.95%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

1.12M

2.22%

-24.96K

-2.17%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

WisdomTree BioRevolution Fund

1.92%

iShares Neuroscience and Healthcare ETF

0.79%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Global X Genomics & Biotechnology ETF

0.51%

JPMorgan Fundamental Data Science Small Core ETF

0.32%

ALPS Medical Breakthroughs ETF

0.29%

SPDR S&P Biotech ETF

0.16%

Direxion Daily S&P Biotech Bull 3X Shares

0.09%

iShares Health Innovation Active ETF

0.09%

Fidelity Enhanced Small Cap ETF

0.08%

Ver Mais

WisdomTree BioRevolution Fund

Proporção1.92%

iShares Neuroscience and Healthcare ETF

Proporção0.79%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0.68%

Global X Genomics & Biotechnology ETF

Proporção0.51%

JPMorgan Fundamental Data Science Small Core ETF

Proporção0.32%

ALPS Medical Breakthroughs ETF

Proporção0.29%

SPDR S&P Biotech ETF

Proporção0.16%

Direxion Daily S&P Biotech Bull 3X Shares

Proporção0.09%

iShares Health Innovation Active ETF

Proporção0.09%

Fidelity Enhanced Small Cap ETF

Proporção0.08%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados